Item 7.01. Regulation FD Disclosure.
On January 10, 2022, Scholar Rock Holding Corporation (the “Company”) issued a
press release announcing a corporate update and highlighting priorities for
2022. A copy of the press release is being furnished as Exhibit 99.1 to this
report on Form 8-K.
On January 4, 2022, the Company announced that management will present at the
40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at
7:30 a.m. EST. A copy of the presentation slide deck that will be presented is
being furnished as Exhibit 99.2 to this report on Form 8-K. A live webcast of
the presentation may be accessed by visiting the Investors & Media section of
the Scholar Rock website at http://investors.scholarrock.com.
The information in this report furnished pursuant to Item 7.01 and Exhibits 99.1
and 99.2 shall not be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section. It may only be incorporated by
reference in another filing under the Exchange Act or the Securities Act of
1933, as amended, if such subsequent filing specifically references the
information furnished pursuant to Item 7.01 and Exhibits 99.1 and 99.2 of this
Item 8.01. Other Events.
On December 19, 2018, Gilead Sciences, Inc. (“Gilead”) and Scholar Rock, Inc.
(“Scholar Rock”) entered into a three-year collaboration to discover and develop
therapeutics that target TGF?-driven signaling, a central regulator of fibrosis
(the “Collaboration Agreement”). On January 6, 2022, Scholar Rock entered into a
letter agreement with Gilead which (i) confirmed that the collaboration period
under the Collaboration Agreement had expired as of December 19, 2021, and (ii)
the parties agreed the option exercise period for all programs under the
Collaboration Agreement had been terminated as of date of the letter agreement.
The foregoing description of the letter agreement does not purport to be
complete and is qualified in its entirety by reference to the letter agreement,
which we intend to file as an exhibit to our Form 10-Q for the quarter ending
March 31, 2022.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press Release issued by the Company on January 10, 2022, furnished hereto. 99.2 Presentation slide deck, furnished hereto.
© Edgar Online, source Glimpses